Dergiler / Marmara Medical Journal / 1999 / Cilt: 12 - Sayı: 4

COMPARISON OF PROSTATE SPECIFIC ANTIGEN DENSITY IN PATIENTS WHO HAD UNDERGONE RADICAL RETROPUBIC PROSTATECTOMY WITH PSA LEVELS BETWEEN 4.0 TO 1 0.0 NG./ML. AND HISTOPATHOLOGICAL EXAMINATION

Sayfa
186–190
Yayın Tarihi
2016-12-03
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Furthermore, 39% of them had organ confined disease while 6% had lymphatic invasion.Key Words: Prostate carcinoma, Prostate specific antigen, Prostate specific antigen density, Pathological stage

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: We analyzed PSA density in patients who had undergone radical retropubic prostatectomy (RRP) with PSA levels between 4.0 to 10.0 ng/ml and compared these values to histopathological examination.Methods: Between July 1992 and December 1997, we performed 117 radical retropubic prostatectomies for clinically localized prostatic carcinoma.
📊
Temel Bulgular & Veri:Thirty patients whose serum PSA levels were between 4.0 to10.0 ng/ml, were selected as the study group among all.
💡
Sonuç & Katkı:Furthermore, 39% of them had organ confined disease while 6% had lymphatic invasion.Key Words: Prostate carcinoma, Prostate specific antigen, Prostate specific antigen density, Pathological stage
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: We analyzed PSA density in patients who had undergone radical retropubic prostatectomy (RRP) with PSA levels between 4.0 to 10.0 ng/ml and compared these values to histopathological examination.Methods: Between July 1992 and December 1997, we performed 117 radical retropubic prostatectomies for clinically localized prostatic carcinoma. Thirty patients whose serum PSA levels were between 4.0 to10.0 ng/ml, were selected as the study group among all. No patients received neoadjuvant therapy, including androgen deprivation or radiation therapy. The age, preoperative PSA level (Hybritech Tandem assay), PSA density, transrectal ultrasound and Gleason pattern score of transrectal ultrasound guided biopsy and prostatectomy specimens were examined.Results: The age of the patients ranged from 56 to 76 years and the mean age was 63.83 ± 5.01 years. Preoperative PSA levels ranged between 4.0 to 10.0 ng/ml. The mean value was 7.0 ± 1.60 ng/ml. The follow up period of the patients was between 21 and 78 months. The mean follow up was 49.8 ± 14.79 (median: 51) months. Prostate volume ranged from 18 to 110 cc and mean prostate volume was 44.81 ±23.02 cc (median: 42.50 cc). PSA density ranged from0.08 to 0.55 ng/ml/cc, mean PSA density was 0.19 ±0.11 ng/ml/cc (median: 0.15 ng/ml/cc). Using 0.15 PSA density as the cut point, 12 (40%) patients had PSA density <0.15 ng/ml/cc. Of these, radical prostatectomy specimen pathological stage was pT2 in 4 (33%) cases, pT3a in 5 (42%), pT3c in 3 (25%). No patient had lymphatic invasion. PSA density was >0.15 ng/ml/cc in 18 (60%) patients. Of these, radical prostatectomy specimen pathological stage was pT2 in 7 (39%) cases, pT3a in 8 (44%), pT3c in 3 (17%) and 1 patient (6%) had lymph node positive. The followup of PSA levels revealed recurrence in 6 (20%) patients. The period of these recurrences: mean time to recurrence was 17.3 ± 19.54 (median: 24.5 months) months with a range of 3 and 53 months. Five of 6 patients (83%) had PSA density >0.15 ng/ml/cc.Conclusion: There is still some controversy regarding the treatment algorithm in cases with prostate cancer and PSA levels between 4.0 to 10.0 ng/ml. Recent studies, have underlined that free to total serum PSA ratio has a higher specificity than PSA density for cases with a PSA levels between 4.0 to 10.0 ng/ml in detecting and screening prostate cancer. But, PSA density has shown to be > 0.15 ng/ml/cc in 60% cases who had undergone radical retropubic prostatectomy for localized prostate cancer and PSA levels between4.0 to 10.0 ng/ml. Furthermore, 39% of them had organ confined disease while 6% had lymphatic invasion.Key Words: Prostate carcinoma, Prostate specific antigen, Prostate specific antigen density, Pathological stage

🔖

Bu Makaleye Atıf Yap

KOKSAL, T., TUNÇ, M., ORHAN, İ., USTA, M., KILIÇASLAN, İ., ESEN, T. (2016). COMPARISON OF PROSTATE SPECIFIC ANTIGEN DENSITY IN PATIENTS WHO HAD UNDERGONE RADICAL RETROPUBIC PROSTATECTOMY WITH PSA LEVELS BETWEEN 4.0 TO 1 0.0 NG./ML. AND HISTOPATHOLOGICAL EXAMINATION. Marmara Medical Journal, Cilt: 12 - Sayı: 4, 186–190. https://ajindex.com/articles/688761

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (9)

  1. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991.145:907-923.
  2. Catalona JC, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. Hew Engl J Med 1991:324:1 156-1 161. Catalona WJ, Richie JP, Ahmann PR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994:151:1283-1290.
  3. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin north Am 1997,24:283- 291. Partin AW, Carter fIB, Chan DW, et ai. Prostate specific antigen in the staging of localized prostate cancer. Influence of tumor differentiation, tumor volume and benign hiperplasia. J Urol 1990:143:747-752.
  4. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142:1011-1017.
  5. Lange PH, Ercole CJ, Lightner DJ, et al. The value of prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141:873- 879. Benson MC, Whang IS, Olsson CA. The use of prostate specific antigen density to enhance the predictive value of intermadiate levels of serum PSA. J Urol 1992; 147:81 7-821.
  6. Oesterling JE, Jacobsen SJ, Chute CO, et al. Serum prostate specific antigen in a community-based population of healthy man: establishment of age specific reference ranges. JAMA 1993:270:860- 864. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994; 152:1163- 1 167. 1. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 1995:274:1214-1220.
  7. Zlotta AR, Djavan B, Marberger M, et al. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J Urol 1997; 157:1315-1321. Gleason DP. Classification of prostatic carcinoma. Cancer Chemother Rep ¡966:50:125-128.
  8. Esteve J, Kricker A, Ferlay J, et al. Facts and figures of cancer in the European cummunity. Lyon, France: International agency for research on cancer 1993:1-26.
  9. Epstein Jl, Walsh P, Brendler CB. Radical prostatectomy for Impalpable prostate ca